Search results for "Intestinal Neoplasm"

showing 10 items of 73 documents

Anti-cancer activity of di- and tri-organotin(IV) compounds with D-(+)-Galacturonic acid on human tumor cells

2018

Abstract We have compared the anti-proliferative activity in vitro, of R2SnGala (1-3) [R = Me, n-Bu, Ph] and novel R3SnGala (4, 5) [R = Me, n-Bu] with D-(+)-Galacturonic acid [HGala; Galaq-, q = (2) and (1) for R2SnGala and R3SnGala, respectively] compounds, towards human tumor cell lines of intestinal carcinoma (HCT-116) and breast adenocarcinoma (MCF-7). The new synthesized 4 and 5 compounds were characterized, in solution, by 1H, 13C and 119Sn NMR, that showed that HGala acts as monoanionic moiety and evidenced the dynamic behavior of the compounds, due to inter-conversions involving the anomeric carbon atom of the ligand. Cell viability, apoptosis induction and cell cycle distribution w…

Anti cancerCarbohydrateCell SurvivalHCT-116Antineoplastic AgentsApoptosisBreast NeoplasmsOrganotin(IV)Adenocarcinoma010402 general chemistry01 natural sciencesBiochemistryFlow cytometryInorganic ChemistryOrganotin(IV); D-(+)-Galacturonic acid; NMR; Anti cancer; HCT-116; MCF-7Intestinal NeoplasmsmedicineOrganotin CompoundsCytotoxic T cellHumansViability assayCytotoxicityD-(+)-Galacturonic acidmedicine.diagnostic_testAnti-proliferative010405 organic chemistryCell growthChemistryHexuronic AcidsMCF-7 .Cell cycleHCT116 CellsMolecular biologyNMR0104 chemical sciencesCell cultureApoptosisSettore CHIM/03 - Chimica Generale E InorganicaMCF-7 CellsMCF-7Caco-2 Cells
researchProduct

The human gene encoding cytokeratin 20 and its expression during fetal development and in gastrointestinal carcinomas

1993

The differentiation of the predominant cell types of the mucosal epithelium of the mammalian gastrointestinal tract is characterized by increasing amounts of an intermediate-sized filament (IF) protein designated cytokeratin (CK) 20 which is a major cellular protein of mature enterocytes and goblet cells. Here we report the isolation of the human gene encoding CK 20, its complete nucleotide sequence and the amino acid sequence deduced therefrom that identifies this polypeptide (mol. wt. 48553) as a member of the type I-CK subfamily. Remarkable, however, is the comparably great sequence divergence of CK 20 from all other known type I-CKs, with only 58% identical amino acids in the conserved …

Cancer ResearchCell typeMolecular Sequence DataGene ExpressionKeratin-20AdenocarcinomaBiologyImmunoenzyme TechniquesEmbryonic and Fetal DevelopmentCytokeratinIntermediate Filament ProteinsIntestinal mucosaGastric mucosamedicineHumansAmino Acid SequenceRNA MessengerNorthern blotCloning MolecularMolecular BiologyCells CulturedGastrointestinal NeoplasmsGastrointestinal tractBase SequenceSequence Homology Amino AcidCell BiologyMolecular biologyIntestinesmedicine.anatomical_structureGenetic CodeCell cultureImmunologyEnterochromaffin cellDevelopmental BiologyDifferentiation
researchProduct

Cytoskeletal differences between human neuroendocrine tumors: A cytoskeletal protein of molecular weight 46,000 distinguishes cutaneous from pulmonar…

1985

The cytoskeletons of various human neuroendocrine (NE) tumors were analyzed immunohistochemically using antibodies against intermediate-filament (IF) proteins as well as by two-dimensional gel electrophoresis of proteins from microdissected tissue samples. All of the tumors studied were found to contain cytokeratin filaments and are therefore referred to as 'NE tumors of the epithelial type'. In addition, neurofilaments were found in most cutaneous and some pulmonary NE tumors, as well as in medullary carcinomas of the thyroid and in pancreatic islet cell tumors. The neurofilament staining was frequently concentrated in cytoplasmic IF aggregates. Gel-electrophoretic analyses showed that all…

Cancer ResearchPathologymedicine.medical_specialtyLung NeoplasmsSkin NeoplasmsNeurofilamentCarcinoid TumorHistogenesisBiologyNeuroendocrine tumorsDiagnosis DifferentialCytokeratinIntestinal NeoplasmsKeratinmedicineCarcinomaHumansThyroid NeoplasmsCarcinoma Small CellMolecular Biologychemistry.chemical_classificationThyroidCell Biologymedicine.diseaseNeoplasm ProteinsMolecular WeightPancreatic NeoplasmsCytoskeletal Proteinsmedicine.anatomical_structurechemistryImmunologyPancreasDevelopmental BiologyDifferentiation
researchProduct

The expression of HSP60 and HSP10 in large bowel carcinomas with lymph node metastase

2005

Abstract Background The involvement of Heat Shock Proteins (HSP) in cancer development and progression is a widely debated topic. The objective of the present study was to evaluate the presence and expression of HSP60 and HSP10 in a series of large bowel carcinomas and locoregional lymph nodes with and without metastases. Methods 82 Astler and Coller's stage C2 colorectal cancers, of which 48 well-differentiated and 34 poorly-differentiated, were selected along with 661 lymph nodes, including 372 with metastases and 289 with reactive hyperplasia only, from the same tumours. Primitive tumours and both metastatic and reactive lymph nodes were studied; specifically, three different compartment…

Cancer ResearchPathologymedicine.medical_specialtyTime FactorsColonColorectal cancerBlotting Westernlcsh:RC254-282Surgical oncologyIntestinal NeoplasmsBiomarkers TumorChaperonin 10GeneticsmedicineCarcinomaHumansIntestine LargeNeoplasm MetastasisStage (cooking)Lymph nodeInflammationAnalysis of VarianceHyperplasiabusiness.industryCarcinomaCell DifferentiationChaperonin 60Hyperplasialcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseImmunohistochemistryGene Expression Regulation Neoplasticmedicine.anatomical_structureOncologyLymphatic MetastasisDisease ProgressionImmunohistochemistryhspLymph NodesLymphbusinessResearch ArticleBMC Cancer
researchProduct

Intestinal epithelial HuR modulates distinct pathways of proliferation and apoptosis and attenuates small intestinal and colonic tumor development.

2014

Abstract HuR is a ubiquitous nucleocytoplasmic RNA-binding protein that exerts pleiotropic effects on cell growth and tumorigenesis. In this study, we explored the impact of conditional, tissue-specific genetic deletion of HuR on intestinal growth and tumorigenesis in mice. Mice lacking intestinal expression of HuR (Hur IKO mice) displayed reduced levels of cell proliferation in the small intestine and increased sensitivity to doxorubicin-induced acute intestinal injury, as evidenced by decreased villus height and a compensatory shift in proliferating cells. In the context of Apcmin/+ mice, a transgenic model of intestinal tumorigenesis, intestinal deletion of the HuR gene caused a three-fo…

Cancer ResearchPost-translational regulationRNA-binding proteinContext (language use)ApoptosisCell Growth ProcessesBiologymedicine.disease_causeArticleAU-rich RNAMiceGene expressionIntestinal NeoplasmsmedicineAnimalsmRNA stabilityIntestinal MucosaMice KnockoutCell growthMolecular biologyPhenotypeProtein-RNA interactionSmall intestineDisease Models Animalmedicine.anatomical_structureOncologyELAV ProteinsApoptosisColonic NeoplasmsCancer researchCarcinogenesis
researchProduct

Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controv…

2016

Contains fulltext : 171468pub.pdf (Publisher’s version ) (Open Access) Primary treatment of rectal cancer was the focus of the second St. Gallen European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Cancer Conference. In the context of the conference, a multidisciplinary international expert panel discussed and voted on controversial issues which could not be easily answered using published evidence. Main topics included optimal pretherapeutic imaging, indication and type of neoadjuvant treatment, and the treatment strategies in advanced tumours. Here we report the key recommendations and summarise the related evidence. The treatment strategy for localised rect…

Cancer ResearchStagingColorectal cancermedicine.medical_treatmentNeoplasias Gastrointestinais030230 surgerySYNCHRONOUS LIVER METASTASESImagingCOLORECTAL-CANCER0302 clinical medicineADJUVANT CHEMOTHERAPYTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]SHORT-COURSE RADIOTHERAPYRectal cancerNeoadjuvant therapyGastrointestinal NeoplasmsRectal Neoplasms/drug therapyCombination chemotherapyChemoradiotherapyCombined Modality TherapyTotal mesorectal excisionNeoadjuvant TherapyEuropeNeoplasias do Recto/quimioterapiaOncology030220 oncology & carcinogenesisMEDIAN FOLLOW-UPLife Sciences & BiomedicineDiagnostic Imagingmedicine.medical_specialtyAntineoplastic AgentsLOCAL RECURRENCERisk AssessmentCOURSE PREOPERATIVE RADIOTHERAPY03 medical and health sciencesmedicineHumansGastrointestinal cancerOncology & CarcinogenesisRadiochemotherapyNeoplasm StagingScience & TechnologyRadiotherapyRectal Neoplasmsbusiness.industryGeneral surgeryTOTAL MESORECTAL EXCISIONCancerRANDOMIZED PHASE-IIImedicine.diseaseSurgeryRadiation therapySurgerybusiness1112 Oncology And CarcinogenesisChemoradiotherapyPOSTOPERATIVE CHEMORADIOTHERAPY
researchProduct

Expression and regulation by interferon-γ of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours

1999

The membrane-bound complement inhibitors CD46 (membrane cofactor protein), CD55 (decay-accelerating factor) and CD59 (protectin) protect tumour cells against lysis by activated complement. In this study, a total of 14 (3 gastric, 3 colonic and 8 pancreatic) gastrointestinal tumour cell lines were examined for the expression of CD46, CD55 and CD59 with respect to the regulatory efficacy of interferon-gamma (IFN-gamma). The effects of IFN-gamma on mRNA and protein expression levels of CD46, CD55 and CD59 were evaluated by Northern blot hybridisation, RT-PCR, flow cytometry and immunostaining. In unstimulated cell lines, CD46 and CD59 transcripts were expressed at comparable levels, whereas th…

Cancer Researchmedicine.medical_treatmentCD59 AntigensCD59BiologyMembrane Cofactor ProteinInterferon-gammaComplement inhibitorComplement Inactivator ProteinsAntigens CDmedicineHumansRNA MessengerNorthern blotGastrointestinal NeoplasmsComplement Inactivator ProteinsMembrane GlycoproteinsCD55 AntigensReverse Transcriptase Polymerase Chain ReactionCD46Blotting NorthernFlow CytometryBlotBlotting SouthernCytokineOncologyCancer researchImmunostainingEuropean Journal of Cancer
researchProduct

Factors influencing inclusion in digestive cancer clinical trials: A population-based study

2015

Inclusion in a randomized therapeutic trial represents an optimal therapeutic strategy.To determine the influence of demographic characteristics and deprivation on the enrolment of patients in digestive cancer clinical trials.Between 2004 and 2010, 4632 patients were recorded by the Burgundy Digestive Cancer Registry. According to a balancing score, the 136 patients included in a clinical trial were matched with 272 patients who met the eligibility criteria for trials. Deprivation was measured by the ecological European deprivation index. A conditional multivariate logistic regression was performed.Patients aged over 75 years were significantly less likely to be included in clinical trials …

Clinical Trials as TopicPediatricsmedicine.medical_specialtyMultivariate analysisHepatologybusiness.industryPatient SelectionAge FactorsGastroenterologyOdds ratioLogistic regressionClinical trialPopulation based studyLogistic ModelsSocioeconomic FactorsMultivariate AnalysismedicineHumansRegistriesbusinessInclusion (education)Digestive cancerGastrointestinal NeoplasmsTherapeutic strategyDigestive and Liver Disease
researchProduct

Confocal laser endomicroscopy for gastrointestinal diseases.

2008

Confocal laser endomicroscopy enables in vivo microscopy of the mucosal layer of the gastrointestinal tract with subcellular resolution during ongoing endoscopy. Endomicroscopy opens the door to immediate tissue and vessel analysis. Different types of diseases can be diagnosed with optical surface and subsurface analysis. Analysis of the in vivo microarchitecture can be used for targeting biopsies to relevant areas, and subsurface imaging can unmask microscopic diseases or bacterial infection. Molecular imaging is becoming feasible, which will enable new indications in gastrointestinal endoscopy. This article reviews the current and rapidly expanding clinical data on endomicroscopy and give…

Confocal laser endomicroscopyPathologymedicine.medical_specialtyMicroscopy Confocalmedicine.diagnostic_testbusiness.industryColonGastrointestinal DiseasesGastroenterologyfood and beveragesColitisEndoscopy GastrointestinalEndoscopyBarrett EsophagusCeliac DiseaseOptical surfaceEndomicroscopyMedicineIn vivo microscopyHumansVessel analysisMolecular imagingbusinessGastrointestinal endoscopyGastrointestinal NeoplasmsGastrointestinal endoscopy clinics of North America
researchProduct

Advanced imaging of the gastrointestinal tract: research vs. clinical tools?

2009

Diagnostic endoscopy has moved forward considerably in the recent years. Still, three major needs have to be satisfied: endoscopy should be able to detect a lesion, characterize the lesion, and then its nature should be confirmed. These steps should ideally translate into an immediate therapeutic decision.High definition endoscopy has optimized our endoscopic view onto the mucosa and can be combined with digital surface enhancement modalities. Chromoendoscopy still holds a place to detect especially flat lesions in high-risk patients such as ulcerative colitis. Digital chromoendoscopy techniques such as narrow band imaging, i-scan, or Fuji intelligent chromo endoscopy offer new possibilitie…

Confocal laser endomicroscopymedicine.medical_specialtyGastrointestinal tractBiomedical ResearchNarrow-band imagingmedicine.diagnostic_testbusiness.industryHigh definition endoscopyGastroenterologyChromoendoscopyEndoscopyDiagnosis DifferentialLesionAutofluorescencemedicineHumansEndoscopy Digestive SystemRadiologymedicine.symptombusinessGastrointestinal NeoplasmsCurrent Opinion in Gastroenterology
researchProduct